Clinical Prognostic Factors Associated With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
Matthew Human, Christopher G.S. Gilmartin, Athanasios Papathanasiou, Christopher R. Tench, Pakeeran Siriratnam, Chiara Rocchi, Bruno Gran, Milan Hargovan, Ei Zune The, James A. Varley, Saif Huda, Radu Tanasescu · 2026
Read Clinical Prognostic Factors Associated With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease by Matthew Human, Christopher G.S. Gilmartin, Athanasios Papathanasiou, Christopher R. Tench, Pakeeran Siriratnam, Chiara Rocchi, Bruno Gran, Milan Hargovan, Ei Zune The, James A. Varley, Saif Huda, Radu Tanasescu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13537470.txt.
Description
Matthew Human and co-authors hunt signs of relapse in a nerve disease tied to antibodies in a study from two thousand twenty-six. The disease, MOGAD, attacks myelin, the coating on nerves. After a first attack, who will relapse is hard to foretell.
The team modeled one hundred one patients from three UK centers. Longer steroid cover after the first attack, at least ten milligrams for three months, linked to a lower relapse risk. The pattern held clearly in one check data set and pointed the same way in another. Staying antibody-positive, age, sex, and first-attack eye inflammation did not predict relapse. Time-to-relapse checks backed the steroid finding.
Catalog record
| CREATOR | Matthew Human, Christopher G.S. Gilmartin, Athanasios Papathanasiou, Christopher R. Tench, Pakeeran Siriratnam, Chiara Rocchi, Bruno Gran, Milan Hargovan, Ei Zune The, James A. Varley, Saif Huda, Radu Tanasescu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |